SFX by Ex Libris Inc.

Users interested in this article also expressed an interest in the following:
description	1.	Meyer, C. "Genomic DNA of leukemic patients: Target for clinical diagnosis of MLL rearrangements." Biotechnology journal (2006): 656-663.
description	2.	Langebrake, C. "Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group." Journal of clinical oncology 24.22: 3686-3692.
description	3.	Rubnitz, Jeffrey E. "Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial." The lancet oncology 11.6 (2010): 543-552.
description	4.	Abd-El-Ghaffar, A. "P-Glycoprotein (P-170) expression in acute leukemias." Hematology 11.1 (2006): 35-41.
description	5.	Ragueneau, O. "Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia." The Journal of clinical pharmacology 44.8 (2004): 873-880.
description	6.	Goulden, D. "Minimal residual disease directed therapy for childhood acute myeloid leukaemia: the time is now." British journal of haematology 134.3 (2006): 273-282.
description	7.	Gilliland, D Gary G. "The molecular basis of leukemia." Hematology 2004.1 (2004): 80-97.

Select All Clear All Save Citations

Proceedings of the National Academy of Sciences of the United States of America [0027-8424] Meyer, C yr:2004